Medicamen Organics share price
NSE: MEDIORGPharmaceuticals & Biotechnology
Last close ₹24.55down ₹0.90 (3.54%)
Share price at the NSE close on 23 Oct 2026. Previous close ₹25.45.
52-week range of traded prices to 23 Oct 2026
₹19.10Low, 12 Jun 2026₹38.00High, 23 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price.
- ₹37 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 29 May 2026
- −13.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.50
- Volume, NSEVolume. Shares traded on the last trading day.
- 2,000
Results
Consolidated; ₹ crore, the charts by years to March, the table by half year.Half-yearly results
Half year to Mar 2026, against the half year beforeFiled 29 May
- RevenueRevenue. The pill is the change in revenue against the half year before: this period's figure divided by that one's, less one, in per cent.
- ₹4.78 Crdown 73.24%
- Net profitNet profit. Under it, net profit in the half year before. A change in per cent is not worked out where either period is a loss or nothing.
- −₹6.06 CrHalf year to Sep 2025: ₹2.04 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- −126.8%
Revenue by year
Peak revenue ₹38 Cr, year to Mar 2025
Net profit by year, a loss in red
- Net profit
- Loss
A loss in the year to Mar 2026, −₹4.02 Cr
| ₹ crore | Sep 2024Filed 31 May | Mar 2025Filed 31 May | Sep 2025Filed 15 Nov | Mar 2026Filed 29 May |
|---|---|---|---|---|
| Revenue | 16.6 | 21.6 | 17.9 | 4.8 |
| Net profit | 1.5 | 2.5 | 2.0 | −6.1 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 9.1% | 11.8% | 11.4% | −126.8% |
Consolidated. The 4 half years from Sep 2024, the first on record. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −2.8% | – | – | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 1 year is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Medicamen Organics in market cap. 1 company in the table last traded before then: its row is priced on its last trade.
Medicamen Organics is not on the chart: it has no P/E today
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Mangalam Drugs and OrganicsMANGALAM | 45 | – | 0.4 | – | −22.3% | – | −30.3% | −12.9% | 0.00% |
 ANG Lifesciences IndiaANG | 43 | – | 0.8 | – | −15.6% | – | −22.8% | −6.3% | 0.00% |
 Vasundhara RasayansVRL | 43 | 7.3 | 1.0 | 6.8 | +3.5% | +49.9% | 15.4% | 13.3% | 1.48% |
 Kabra DrugsKABRADG | 38 | 5.0 | 1.3 | 3.3 | +1,743.5% | – | 28.0% | 28.4% | 0.00% |
 Vista PharmaceuticalsVISTAPH | 36 | – | 1.0 | – | −60.4% | – | −28.7% | −32.5% | 0.00% |
 Rajnish WellnessRAJNISH | 35 | – | 0.3 | – | +356.9% | – | – | −8.2% | 0.00% |
 Roopa IndustriesROOPAIND | 34 | 269.3 | 2.0 | 7.7 | +3.7% | −93.7% | 0.7% | 15.4% | 0.00% |
 Jfl Life SciencesJFLLIFE | 34 | 5.0 | 0.7 | 4.6 | – | – | 15.9% | 15.9% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Share news and announcements
Sep 2026
26 Sep · Management
Aug 2026
27 Aug · Board meeting
Jul 2026
21 Jul · Management
Medicamen Organics share price by year
Each calendar year to 2025.Medicamen Organics share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 24.00 | −55.5% | 54.45 | 20.45 |
| 2024 | 53.90 | – | 151.90 | 47.00 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2024 is from its first session, 28 Jun 2024.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 24.55 | 24.55 | 24.55 | 24.55 | 24.55 | 2,000 | – |
| 21 Oct 2026 | 25.45 | 25.45 | 25.45 | 25.45 | 25.45 | 4,000 | 50.0% |
| 16 Oct 2026 | 26.75 | 26.75 | 26.75 | 26.75 | 26.75 | 4,000 | 100.0% |
| 15 Oct 2026 | 26.00 | 26.75 | 26.00 | 26.75 | 26.38 | 4,000 | 100.0% |
| 14 Oct 2026 | 26.40 | 26.40 | 26.40 | 26.40 | 26.40 | 2,000 | 100.0% |
| 13 Oct 2026 | 22.85 | 25.20 | 22.85 | 25.20 | 25.03 | 36,000 | 94.4% |
| 12 Oct 2026 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 | 6,000 | 100.0% |
| 9 Oct 2026 | 24.00 | 24.00 | 23.35 | 23.35 | 23.48 | 10,000 | 100.0% |
| 1 Oct 2026 | 24.55 | 24.55 | 24.55 | 24.55 | 24.55 | 2,000 | 100.0% |
| 29 Sep 2026 | 23.95 | 24.05 | 23.95 | 24.05 | 24.04 | 24,000 | 91.7% |
Prices in ₹ per share as traded, not adjusted.
Company details
- Legal name
- Medicamen Organics Limited
- NSE symbol
- MEDIORG
- ISIN
- INE0PE401018
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Jun 2024
- Face value
- ₹10